tradingkey.logo
tradingkey.logo
Search

Telomir Pharmaceuticals Inc

TELO
Add to Watchlist
1.260USD
-0.010-0.79%
Close 05/15, 16:00ETQuotes delayed by 15 min
43.32MMarket Cap
LossP/E TTM

Telomir Pharmaceuticals Inc

1.260
-0.010-0.79%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-0.79%

5 Days

-3.08%

1 Month

-5.97%

6 Months

-6.67%

Year to Date

-5.26%

1 Year

-49.60%

Key Insights

Telomir Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 119 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 15.50.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Telomir Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
119 / 155
Overall Ranking
474 / 4482
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Telomir Pharmaceuticals Inc Highlights

StrengthsRisks
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
Fairly Valued
The company’s latest PE is -4.43, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 3.42M shares, increasing 12.50% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 1.38K shares of this stock.

Analyst Rating

Based on 0 analysts
--
Current Rating
15.500
Target Price
+1160.16%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Telomir Pharmaceuticals Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Telomir Pharmaceuticals Inc Info

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
Ticker SymbolTELO
CompanyTelomir Pharmaceuticals Inc
CEOAminov (Erez)
Websitehttps://telomirpharma.com/
KeyAI